Omnicell (OMCL)
(Delayed Data from NSDQ)
$44.48 USD
-0.78 (-1.72%)
Updated Aug 30, 2024 03:59 PM ET
After-Market: $44.31 -0.17 (-0.38%) 7:58 PM ET
3-Hold of 5 3
B Value A Growth A Momentum A VGM
Omnicell (OMCL) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Downside to Average Price Target |
---|---|---|---|
$41.50 | $61.00 | $30.00 | -6.70% |
Price Target
Based on short-term price targets offered by six analysts, the average price target for Omnicell comes to $41.50. The forecasts range from a low of $30.00 to a high of $61.00. The average price target represents a decline of 6.7% from the last closing price of $44.48.
Analyst Price Targets (6 )
Broker Rating
Omnicell currently has an average brokerage recommendation (ABR) of 2.25 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by eight brokerage firms. The current ABR compares to an ABR of 2.25 a month ago based on eight recommendations.
Of the eight recommendations deriving the current ABR, three are Strong Buy, representing 37.5% of all recommendations. A month ago, Strong Buy represented 37.5%.
Broker Rating Breakdown
![Broker Rating Visualization](https://widget3.zacks.com/images/charts/bar/brokerage/bar/OMCL.png)
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 3 | 3 | 3 | 3 | 3 |
Buy | 0 | 0 | 0 | 0 | 0 |
Hold | 5 | 5 | 5 | 4 | 4 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 1 | 1 |
ABR | 2.25 | 2.25 | 2.25 | 2.50 | 2.50 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
8/14/2024 | KeyBanc Capital Markets | Scott Schoenhaus | Hold | Hold |
8/5/2024 | Piper Sandler | Jessica E Tassan | Strong Buy | Strong Buy |
8/2/2024 | Not Identified | Not Identified | Strong Sell | Hold |
8/2/2024 | Wells Fargo Securities | Stan Berenshteyn | Hold | Hold |
5/3/2024 | BTIG | David M Larsen | Hold | Hold |
4/30/2024 | The Benchmark Company | William Sutherland | Strong Buy | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 2.25 |
ABR (Last week) | 2.25 |
# of Recs in ABR | 8 |
Average Target Price | $41.50 |
LT Growth Rate | 1.40% |
Industry | Medical Info Systems |
Industry Rank by ABR | 69 of 253 |
Current Quarter EPS Est: | 0.41 |